Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation BTK inhibitor.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., October 13, 2023 BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase inhibitor (BTKi), in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicul
Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company. As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa. "BeiGene's work is original, and we will vigorously defend against all allegations of patent inf
BeiGene's BTKi is approved in more than 65 markets globally BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a